Evidence map›Paper›PMID 42032301›Full record

ArticleNature immunology2026

IL-9 and Blimp-1 protect the transcriptional identity of group 2 innate lymphocytes in allergic asthma.

Yibo Zheng, Shilpi Giri, Jinyi Zhang, Yijia Chen, Aaron Yang, Sagar L Kale, Harshita Beeravolu, Abbe Pannucci, Anthony D Marinov, Jeremy S Tilstra and 9 more

Abstract read
In one paragraph

Article in Nature immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Yibo ZhengCenter for Systems Immunology, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Shilpi Giri *Center for Systems Immunology, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Jinyi Zhang *Center for Systems Immunology, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Yijia ChenCenter for Systems Immunology, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Aaron YangCenter for Systems Immunology, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Sagar L KaleDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine and Acute Lung Injury Center of Excellence, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Harshita BeeravoluCenter for Systems Immunology, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Abbe PannucciCenter for Systems Immunology, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Anthony D MarinovDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Jeremy S TilstraDivision of Rheumatology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Kun HeCenter for Systems Immunology, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Arianna CreechProgram in Microbiology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Daniella M SchwartzDivision of Rheumatology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-1660-8438
Rachel A GottschalkCenter for Systems Immunology, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Nicolas BouladouxMetaorganism Unit, Immunology Department, Institut Pasteur, Paris, France.ORCID http://orcid.org/0000-0003-1593-671X
Yasmine BelkaidMetaorganism Unit, Immunology Department, Institut Pasteur, Paris, France.
Anthony R CilloCenter for Systems Immunology, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-3213-3129
Anuradha RayDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine and Acute Lung Injury Center of Excellence, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-6844-8918
Amanda C PoholekCenter for Systems Immunology, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. poholeka@pitt.edu.ORCID http://orcid.org/0000-0002-5587-8940

Funding

Linking steady-state cytokine signaling to alveolar macrophage function in homeostasis and lung infectionR01HL162658 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GOTTSCHALK, RACHEL A · 2022 to 2025
$2.4M
American Lung Association (Lung Association) Innovation AwardNHLBI NIH HHS R01 HL162658Tsinghua University (THU) School of Medicine Education FoundationU.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI153104U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI156093
6 · The paper itself

Abstract

Allergic asthma is driven by type 2 immune responses, including type 2 innate lymphoid cells (ILC2s). Although ILC2s are activated by the tissue alarmins interleukin (IL)-33 and IL-25, these signals do not intrinsically enforce type 2 identity and the mechanisms that maintain type 2 cytokine expression remain unclear. Here we show that allergen-induced IL-33 and IL-25 rapidly induce IL-9, which in turn upregulates the transcriptional repressor Blimp-1 in ILC2s. Blimp-1 sustains type 2 immunity by directly repressing type 1 inflammatory programs, including expression of interferon-γ and tumor necrosis factor. Deletion of Blimp-1 in ILC2s increased type 1 cytokine production and reduced IL-5 and IL-13 expression, eosinophil recruitment and mucus production in the lung. In contrast, IL-9 expression was enhanced in the absence of Blimp-1, leading to increased mast cell recruitment. Together, these findings identify Blimp-1 as a key regulator of ILC2 transcriptional fidelity that stabilizes type 2 inflammation while constraining divergent inflammatory programs during allergic responses.

Indexed as

AsthmaImmunity, InnateInterleukin-9LymphocytesPositive Regulatory Domain I-Binding Factor 1AnimalsCytokinesInterleukin-33LungMiceMice, Inbred C57BLMice, KnockoutTranscription, GeneticCytokinesInterleukin-33Interleukin-9Positive Regulatory Domain I-Binding Factor 1Prdm1 protein, mouse

Identifiers

PMID42032301
PMCPMC13226057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.